AstraZeneca to issue trial update after US agency questions 'outdated' data

AstraZeneca said it had reviewed the preliminary assessment of the primary analysis and found it to be consistent with the interim report

AstraZeneca will release the most up-to-date results from its latest Covid-19 vaccine trial within 48 hours after US health officials publicly criticised the drugmaker for using outdated information in a press release earlier this week.

AstraZeneca said results published on Monday were based on an interim analysis of data through Feb 17. The company said on Tuesday it would "immediately engage" with the independent panel monitoring the trial to share its primary analysis using the most up-to-date efficacy data.

The move comes after the National Institute for Allergy and Infectious Diseases said the monitoring board charged with ensuring the safety